SMA Research News

Archives

• 08/01/09: FSMA funding helps advance promising drug program for SMA at Paratek Pharmaceuticals
• 30/12/08: Progress in FSMA-funded stem cell motor neuron replacement program
• 22/12/08: On the track of a cure for infants’ spinal disease
• 21/12/08: Scientists recreate nerve disease to study it
• 19/12/08: Trophos increases focus on neuroprotection and cardioprotection
• 18/12/08: Delivery of recombinant follistatin lessens disease severity in a mouse model of SMA
• 16/12/08: Molecular therapy for SMA closer to clinical use
• 06/12/08: A two-site ELISA can quantify upregulation of SMN protein by drugs for SMA
• 22/11/08: Rescue of a severe mouse model for SMA by U7 snRNA-mediated splicing modulation
• 19/11/08: Neurons derived from embryonic stem cells restore muscle function after injury
• 14/11/08: New drug bypasses gene mutations
• 14/11/08: Swiss scientists have discovered a protein that helps treat SMA
• 09/10/08: Protein linked to SMA identified
• 17/09/08: Repligen announces publication of positive results with proprietary HDAC inhibitor in Huntington’s Disease model
• 15/09/08: Assay Designs, Inc. and the SMA Foundation announce collaboration to accelerate the discovery of new therapeutics for SMA
• 03/09/08: Stem cell transplantation benefits mice with childhood motor neuron disease
• 11/08/08: Sustained improvement of SMA mice treated with Trichostatin A plus nutrition
• 31/07/08: Scientists achieve stem-cell milestone
• 25/07/08: Researchers discover key gene for making motor neurons
• 22/07/08: Allen Institute releases spinal cord map
• 07/07/08: An Israeli scorpion set to improve spinal implant surgery
• 25/06/08: First stem cell trials might start in Orange County, California
• 23/06/08: Daily salbutamol in young patients with SMA type II
• 17/06/08: FSMA and Paratek extend and expand drug discovery collaboration for SMA
• 30/05/08: Researchers gain new insights on spinal muscular atrophy
• 28/05/08: How stem cells could fight Lou Gehrig’s disease
• 30/04/08: Plastin 3 is a protective modifier of autosomal recessive SMA
• 07/04/08: Cold Spring Harbor Laboratory scientists devise potential approach to treat SMA
• 24/02/08: A disease in the cross hairs
• 19/02/08: FSMA, University of California stem cell scientist, and California Stem Cell announce collaboration for safety studies of stem cell therapy in SMA
• 11/02/08: UD researchers discover promising technique for repairing gene defect that causes SMA
• 04/01/08: Neuronal SMN expression corrects SMA in severe SMA mice while muscle-specific SMN expression has no effect
• 29/12/07: The effect of hydroxyurea in SMA cells and patients
• 06/12/07: PTC Therapeutics announces additional $1.6 million grant from the SMA Foundation
• 30/11/07: Stem cells target paralysis
• 01/11/07: 2007 SMA Summit on Drug Development
• 28/09/07: Trophos starts phase Ib clinical trial of TRO19622 in SMA
• 27/09/07: SMA Foundation and BG Medicine announce collaboration
• 19/06/07: Trophos describes identification, characterization and broad neuroprotective properties of TRO19622
• 18/06/07: FSMA announces major breakthrough in development of drug candidate for SMA
• 25/04/07: Summaries of presentations at the 2007 Fight SMA Conference
• 23/04/07: Company to commercialize gene-repair technology
• 16/04/07: Fight SMA provides grant to PTC Therapeutics for research into treatment of SMA
• 03/04/07: FSMA and Paratek Pharmaceuticals expand drug discovery collaboration for SMA
• 12/03/07: Correcting RNA splicing may help treat SMA
• 23/02/07: Trichostatin A extends survival in mouse model Of SMA
• 24/12/06: A Utah Doctor gives a boy with a rare disease and his family hope
• 07/12/06: Trophos successfully completes Phase Ib ALS clinical trials for TRO19622
• 30/11/06: EU network seeks cures for rare muscle diseases
• 16/11/06: Novel aminoglycosides increase SMN levels in SMA fibroblasts
• 02/11/06: Randomized, double-blind trial of phenylbutyrate in SMA
• 01/11/06: VASTox receives grant from leading European neuromuscular disease charity
• 17/10/06: VASTox presents promising results from SMA drug discovery programme
• 11/10/06: Lexicon Genetics awarded additional grant for study of SMA
• 08/10/06: FDA approves Zolinza [SAHA] for lymphoma
• 26/08/06: “She shouldn’t even be here”
• 15/08/06: Benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in SMA cells
• 08/08/06: Research update from the June 2006 FSMA-sponsored research meeting
• 26/06/06: Stem cell mix helps paralyzed rats walk
• 24/06/06: Valproate effective in adult SMA
• 20/06/06: New roles for growth factors: Enticing nerve cells to muscles
• 07/06/06: SMA Foundation announces collaboration with PTC Therapeutics
• 06/06/06: Evaluation of second-generation HDAC inhibitors for the treatment of SMA
• 17/05/06: FSMA and Paratek Pharmaceuticals announce drug discovery collaboration for SMA
• 11/05/06: Lexicon Genetics awarded grant from the US Army for study of SMA
• 11/04/06: First evidence of in vivo elevation of the SMN RNA/protein in SMA carriers and patients treated with valproic acid
• 05/03/06: Trophos and TRO19622: FAQs
• 01/03/06: FSMA and Cambria Biosciences partner to find new treatment avenues for SMA
• 15/02/06: Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron
• 31/01/06: Trophos successfully completes phase 1 clinical trials for novel compound to treat neurodegenerative diseases
• 15/01/06: Transplanted neural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1
• 10/01/06: deCODE chemistry and FSMA announce extension of research agreement
• 21/12/05: FSMA and Invitrogen partner to investigate molecular mechanisms of SMA
• 20/12/05: Correction of SMN2 pre-mRNA splicing by antisense U7 snRNAs
• 20/12/05: Stem cells for the treatment of SMA
• 02/12/05: Research update and Q&A session from the June 2005 FSMA Conference
• 04/11/05: Scientists crack code for motor neuron wiring
• 08/10/05: Drug provides glimmer of hope for children suffering fatal genetic disease
• 25/08/05: Hydroxyurea enhances SMN2 gene expression in SMA cells
• 17/08/05: Regular exercise prolongs survival in a type 2 SMA mouse model
• 08/06/05: Exposing SMA-Affected cells to aminoglycoside drugs can increase SMN
• 05/05/05: Utah study is offering hope for ill children
• 20/04/05: Discovery of anti-sense molecules that increase full-length protein from SMN2
• 20/04/05: Research summaries from the FightSMA 2005 Conference
• 29/03/05: Oxford BioMedica receives notice of allowance for its US Lentivector patent
• 06/03/05: Pain Reliever May Provide Clues for Treating Spinal Muscular Atrophy: National Institute of Neurological Disorders and Stroke
• 15/12/04: Trophos initiates phase 1 clinical trial with TRO19622
• 02/07/04: Research update and Q&A session from the June 2004 FSMA Conference
• 07/01/04: FSMA and deCODE open screening capabilities to third-party compounds
• 08/11/03: Paratek Pharmaceuticals and FSMA team up!
• 16/09/03: Two clinical drug safety studies launched in children with SMA
• 12/02/03: FSMA and deCODE launch landmark effort to develop treatment for SMA
• 10/04/02: FSMA update on stem cell research
• 10/10/00: A study of thyrotropin-releasing hormone for the treatment of SMA